Floatz logo

Cyclophosphamide

Leukemia, B-cell

Beijing Immunochina Medical Science & Technology Co., Ltd.Small moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Leukemia, B-cell cohort.

Asset / SponsorPhaseRating
Fludarabine
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 4BBB
Ibrutinib
Loxo Oncology, Inc.
Phase 4BBB
Dasatinib
Nanfang Hospital, Southern Medical University
Phase 2/3B
Tucidinostat
Nanfang Hospital, Southern Medical University
Phase 2/3B
Chimeric Antigen Receptor Modified T Cells Infusion
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC

View all 16 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →